Objective To observe the efficacy and side effect of olanzapine combined with tropisetron, dexamethasone for the pre-vention of highly emetogenic chemotherapy-induced nausea and vomiting ( CINV) . Methods A total of 78 patients with highly emetogen-ic single day chemotherapy were randomly divided into two groups:trial group ( olanzapine combined with tropisetron, dexamethasone n=40) and control group (Tropisetron Combined with Dexamethasone n=38). The control of acute CINV, delayed CINV and adverse reac-tions were observed. Results The control rates of acute vomiting in trial group and control group were 87. 5% vs 81. 6%, 65. 0% vs 57. 9% in acute nausea, 75. 0% vs 52. 6% in delayed vomiting, 32. 5% vs 13. 2% in delayed nausea. The trial group was better than the control group in delayed vomiting and delayed nausea which there was difference between them (P < 0. 05). There was no statistical differ-ence between the two groups in the incidence of adverse reactions (P>0. 05). Conclusion Olanzapine combined with tropisetron, dexa-methasone for the prevention was significantly better than tropisetron combined with dexamethasone in the control of delayed CINV in pa-tients received highly emetogenic chemotherapy.

ObjectiveTo explore the ability of inhibition resistibility of multiple displacement amplification (MDA)in samples with inhibitors. To explain the application and value of MDA in forensic medicine by comparing with using magnetic beads methods(MBM)to purify sample.MethodsDifferent concentra-tions of hemoglobin and humid acid(HA)mixed with DNA samples and then divided the samples into MDA group, MBM group and control group.D3S1358locus was amplified and detected by polyacry-lamide gel electrophoresis detection system and AmpF?STR? IdentifilerTM Plus Kit-capillary electrophore-sis detection system.ResultsWhen hemoglobin concentrations exceed 1 ng/μL or HA concentrations ex-ceed 0.1 ng/μL, amplification products could not be obtained by single-locus system in control group. When hemoglobin concentration exceeds 100 ng/μL or HA concentrations exceed 1 ng/μL, the samples could not be amplified by MBM. Inhibitors in different concentrations were amplified successfully in MDA group without any influence from inhibitors.ConclusionMDA has the capability to remove the inhibi-tion of hemoglobin and HA, which is better than MBM and has a certain value in forensic practices.

Objective To analyze the relative factors of bone marrow suppression after chemotherapy with different-dose carboplatin and paclitaxel (TC) on the patients with ovarian cancer.Methods Sixty-two patients with ovarian cancer admitted in Beijing Obstetrics and Gynecology Hospital from January 2002 to December 2007, using TC regimen ,a total of 196 cycles of chemotherapy ,were divided into two groups by the doses of carboplatin [area under concentration-time curve(AUC) 4 -6 for low-dose,AUC >6 -7 for hight-dose, the carboplatin dose calculated with AUC] or by the doses of paclitaxel (135 -< 150 mg/m2 low-dose,150 - 175 mg/m2 hight-dose). After each TC cycle, the routine blood was test to determine the graduation of the marrow suppression, and then the correlation factors were analyzed with logistic regression. Results (1) The occurrence rate of bone marrow suppression:there were 159 cycles (81.1%) grade 0 - Ⅱ bone marrow suppression, while 37 cycles (18.9%) of grade Ⅲ - Ⅳ. (2) Factors related to bone marrow suppression:the results shown that there were not related to bone marrow suppression,which incluced cellular differentiation, tumor type, height, weight and paclitaxel dose(P>0.05). While,the different cycle, age, the later stages of tumor, serum creatinine concentration, endogenous creatinine clearance rate, AUC values were the relative factors of bone marrow suppression(P =0.000,0.000,0.018,0.033,0.001,0.000). Seven variables were conducted into the logistic regression and the results shown that the different cycles, the age, AUC grades were independent risk factors (P = 0.030,0.043,0.009).(3) When low-dose of paclitaxel was given, the occurrence of bone marrow suppression was related to the carboplatin dose AUC. The higher AUC values for carbopaltin were chosen, the higher of severe bone marrow suppression would happen. (4/14 vs 0,P=0.015). When the dose of high grade of paclitaxel was given, the occurrence of bone marrow suppression in cases with hight-dose carboplatin was statistically significant than that in cases treated with low-dose carboplatin [45.7%(16/35) vs 13.7% (17/124), P=0.000]. Conclusions The independent risk factors of myelosuppression after chemotherapy with TC regime on the patients with ovarian cancer including the cycles, age and AUC values. The carboplatin dose calculating with AUC is related to the occurrence of bone marrow suppression, the higher AUC values for carbopaltin would chosen,the higher of severe bone marrow suppression would be happen.

Child ; Evidence-Based Medicine ; Glomerulonephritis, IGA ; diagnosis ; therapy ; Guidelines as Topic ; Humans

Humans ; Infant ; Infant Food ; Infant, Newborn ; Triazines ; toxicity ; Urinary Calculi ; chemically induced

The morbility of bronchial asthma is gradually increasing year by year all over the world. Numerous studies have demonstrated that bronchial asthma is close related with immunoregulation. Vitamin D3 is involved to immune regulatory mechanisms in bronchial asthma, including regulating cytokine, Treg, matrix metalloproteinases-9. Considering the influence of vitamin D3 on the immune regulatory of bronchial asthma, it is provided a theory evidence that vitamin D can be used in the treatment of bronchial asthma effectivly and a novel method of immune treatment for children with bronchial asthma eventually.

Child ; Diagnosis, Differential ; Humans ; Kidney Diseases ; diagnosis ; genetics ; therapy ; Nephrotic Syndrome ; diagnosis ; therapy ; Prenatal Diagnosis

Child ; Evidence-Based Medicine ; Humans ; Kidney Diseases ; diagnosis ; therapy ; Practice Guidelines as Topic

Child ; Congresses as Topic ; Humans ; Nephrology ; Pediatrics

Biomedical Research ; education ; methods ; trends ; Humans ; Kidney Diseases ; complications ; genetics ; Kidney Failure, Chronic ; genetics ; Meta-Analysis as Topic